These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 11341502

  • 21. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
    Bouma BN, Mosnier LO.
    Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
    [Abstract] [Full Text] [Related]

  • 22. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ, Boon GI, Jansen JW, Bouma BN.
    Thromb Haemost; 1993 Apr 01; 69(4):381-6. PubMed ID: 8497851
    [Abstract] [Full Text] [Related]

  • 23. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN.
    Thromb Haemost; 2000 Jul 01; 84(1):9-14. PubMed ID: 10928462
    [Abstract] [Full Text] [Related]

  • 24. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN.
    Thromb Haemost; 1998 Nov 01; 80(5):829-35. PubMed ID: 9843179
    [Abstract] [Full Text] [Related]

  • 25. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A, Semeraro N.
    Haematologica; 2003 Dec 01; 88(12):1383-9. PubMed ID: 14687992
    [Abstract] [Full Text] [Related]

  • 26. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
    Bouma BN, Mosnier LO, Meijers JC, Griffin JH.
    Thromb Haemost; 1999 Dec 01; 82(6):1703-8. PubMed ID: 10613658
    [Abstract] [Full Text] [Related]

  • 27. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B, Livnat T, Lubetsky A, Tamarin I, Budnik I, Einav Y, Martinowitz U.
    Blood Coagul Fibrinolysis; 2012 Jul 01; 23(5):370-8. PubMed ID: 22498982
    [Abstract] [Full Text] [Related]

  • 28. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
    Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Oct 01; 86(4):1035-9. PubMed ID: 11686321
    [Abstract] [Full Text] [Related]

  • 29. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK, Stewart RJ, Schneider MM, Nesheim ME.
    Anal Biochem; 2004 Jul 15; 330(2):332-41. PubMed ID: 15203340
    [Abstract] [Full Text] [Related]

  • 30. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P.
    Thromb Res; 2000 May 15; 98(4):333-42. PubMed ID: 10822080
    [Abstract] [Full Text] [Related]

  • 31. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 32. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D.
    J Cell Biochem; 1987 Feb 20; 33(2):77-86. PubMed ID: 3553213
    [Abstract] [Full Text] [Related]

  • 33. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
    Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A.
    Thromb Haemost; 2011 Jul 20; 106(1):90-101. PubMed ID: 21544309
    [Abstract] [Full Text] [Related]

  • 34. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
    Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L.
    Thromb Haemost; 1997 Jul 20; 78(1):386-91. PubMed ID: 9198184
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ.
    Thromb Res; 2005 Jul 20; 116(6):519-24. PubMed ID: 16181987
    [Abstract] [Full Text] [Related]

  • 36. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998 Jul 20; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 37. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
    Colucci M, Semeraro N.
    Thromb Res; 2012 Mar 20; 129(3):314-9. PubMed ID: 22113149
    [Abstract] [Full Text] [Related]

  • 38. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
    Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S, Ishii H.
    J Pharmacol Exp Ther; 2004 May 20; 309(2):607-15. PubMed ID: 14762098
    [Abstract] [Full Text] [Related]

  • 39. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
    Flight SM, Masci PP, Lavin MF, Gaffney PJ.
    Blood Coagul Fibrinolysis; 2006 Jul 20; 17(5):417-20. PubMed ID: 16788320
    [Abstract] [Full Text] [Related]

  • 40. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y, Honda Y.
    J Thromb Thrombolysis; 2019 Jul 20; 48(1):103-110. PubMed ID: 30972711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.